Emergent BioSolutions (EBS) Cash & Equivalents (2010 - 2026)

Emergent BioSolutions' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $160.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 7.51% year-over-year to $160.3 million in Q1 2026; TTM through Mar 2026 was $160.3 million, a 7.51% increase from a year earlier, with the FY2025 full-year figure at $205.4 million, up 106.43% from the prior year.
• Cash & Equivalents eased to $160.3 million in Q1 2026 per EBS's latest filing, from $205.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $642.6 million in Q4 2022 and bottomed at $69.7 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $160.3 million (2026), against an average of $224.8 million.
• Across the five-year window, Cash & Equivalents slumped 82.62% in 2023 and jumped 283.5% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $642.6 million in 2022, then slumped by 82.62% to $111.7 million in 2023, then declined by 10.92% to $99.5 million in 2024, then surged by 106.43% to $205.4 million in 2025, then fell by 21.96% to $160.3 million in 2026.
• Per Business Quant, the three latest EBS Cash & Equivalents figures stand at $160.3 million (Q1 2026), $205.4 million (Q4 2025), and $245.5 million (Q3 2025).